3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Allegiant Travel said it drew the full $177.5 million under a previously reported credit facility secured by certain aircraft on October 13, 2026, and separately borrowed $71.8 million under a $231.0 million facility to help fund Boeing 737 MAX pre-delivery payments. The new debt adds to the company's obligations, with repayment of the first facility starting July 2027 and the second due by March 31, 2028 or on aircraft delivery.
October 13, 2026: borrowed the entire $177.5 million under an aircraft-secured facility at a fixed rate, with quarterly amortizing payments starting July 2027 over five to six years
Before the end of third quarter 2026: borrowed $71.8 million under a $231.0 million facility at floating SOFR-based rates to fund Boeing 737 MAX pre-delivery payments
$159.3 million remains undrawn on the $231.0 million facility
Second-facility loans are payable on or before aircraft delivery and no later than March 31, 2028
Change Agents Corporation issued pre-funded warrants to two lenders, Dune Equity Holdings and FirstFire Global Opportunities Fund, in exchange for waiving prepayment provisions tied to a recent note issuance and share sale. The company also executed unsecured promissory notes of $150,000 and $100,000 due December 1, 2026, with amounts due at maturity of $183,335 and $116,665. The warrants may add shares to the 1,254,947 currently outstanding, and a buyout fee applies if stockholder approval is not obtained within 90 days.
Pre-funded warrants issued to Dune for 62,000 shares and to FirstFire for 37,500 shares, at an exercise price of $0.0001 per share
If stockholder approval for the warrant shares is not obtained within 90 days, buyout fees of $150,000 (Dune) and $75,000 (FirstFire) may become payable
Unsecured promissory notes of $150,000 and $100,000 executed October 16, 2026, with amounts due at maturity of $183,335 and $116,665 on December 1, 2026
Chief Strategy Officer Luisa Ingargiola advanced the company $7,500 on October 13, 2026, to cover a loan payment, which was repaid in October 2026
Getty Realty Corp. entered a $200 million senior unsecured term loan and amended its existing credit agreement on October 16, 2026, with the proceeds used to repay revolver borrowings, including funds used for its recently completed Refuel transaction. The amendments also remove a 10.0 basis point SOFR adjustment on revolver borrowings and change the investment grade rating test, which the company says will reduce its revolver borrowing costs.
Term loan principal of $200 million with an effective interest rate of 5.03% at closing
Press release gives a maturity of October 16, 2028 with three twelve-month extension options; the 8-K text gives October 17, 2025
Revolver proceeds repaid; amendment removes the 10.0 basis point SOFR adjustment and allows ratings-based pricing
TCGX Acquisition Corp. II, a blank-check SPAC, closed its initial public offering of 10,000,000 Class A ordinary shares at $10.00 per share, raising $100,000,000 in gross proceeds, and placed the full amount in a U.S. trust account. The company will seek a business combination, with a focus on healthcare and healthcare-related industries, and shareholders' redemption rights depend on whether it completes a deal within 24 months.
IPO of 10,000,000 Class A ordinary shares at $10.00 per share, closed October 19, 2026, for $100,000,000 in gross proceeds
Concurrent private placement of 450,000 shares to the sponsor at $10.00 per share, for $4,500,000
$100,000,000 placed in a trust account at Citibank, N.A.; funds are generally held until a business combination or redemption if none is completed within 24 months
Shares to trade on Nasdaq Capital Market under ticker TCXB beginning October 16, 2026; investors receive no warrants
VenHub Global disclosed that an equity line of credit (ELOC) previously described in its Form S-1 was assigned from Euphoria Capital to Tunim Stone Capital, LLC on October 5, 2026, with the company's signed consent. Tunim Stone assumed all rights and obligations under the ELOC, except for 500,000 commitment shares and their registration rights, which Euphoria Capital retained. The filing does not state financial results or the ELOC's dollar size, so its direct effect on shareholders is not quantified.
Assignment dated October 5, 2026, from Euphoria Capital to Tunim Stone Capital, LLC, with company consent
ELOC was amended September 10, 2026 and deemed effective September 14, 2026, per the Form S-1 filed September 3, 2026
Euphoria Capital retains 500,000 commitment shares and their associated registration rights
Assignment agreement filed as Exhibit 3.1; report signed by CEO Shahan Ohanessian on October 19, 2026
On October 15, 2026, Chefs' Warehouse entered into a $675 million senior secured term loan maturing October 15, 2033, and used the proceeds to repay its prior term loan and redeem its 2.375% convertible notes due 2028. Holders of about $287.2 million of those notes converted into cash and 2,671,056 shares of common stock, which the company issued on October 15, 2026. The filing shows higher secured debt and new share issuance for shareholders to weigh.
New $675 million senior secured term loan matures October 15, 2033, at SOFR plus 2.00% or alternate base rate plus 1.00%.
Prior term loan with a $305 million facility was repaid in full, with about $244.7 million of obligations settled, and terminated.
Holders of about $287.2 million of 2.375% convertible notes due 2028 converted, and 2,671,056 conversion shares were issued on October 15, 2026.
Asset-based loan amendment raised the letter of credit sublimit from $50 million to $75 million.
Eva Live Inc. filed a prospectus supplement on October 19, 2026 to register shares under its September 17, 2026 Equity Purchase Agreement with Hudson Global Ventures, LLC. The agreement lets the company direct the investor to buy up to 5,000,000 shares of common stock, for up to $10 million in aggregate, and the company also issued a warrant for 275,000 shares at $0.01 per share. Shareholders may face dilution if these shares are issued.
Equity Purchase Agreement dated September 17, 2026 allows purchases of up to 5,000,000 shares for up to $10,000,000 in aggregate
Warrant issued to Hudson Global Ventures to buy 275,000 shares at $0.01 per share, exercisable for five years after September 17, 2026
Shares were registered under Form S-3 (File No. 333-294416), declared effective March 24, 2026, plus a prospectus supplement filed October 19, 2026
Installed Building Products, Inc. said it intends to seek a $250 million increase to its existing Term Loan B facility, which is about $500 million. The company expects the add-on to carry the same terms as the existing loan, with net proceeds for general corporate purposes and associated fees, but says completion is subject to market conditions and is not assured. For shareholders, the filing signals additional borrowing, and the company has not yet disclosed completion or final terms.
Seeks to increase the approximately $500 million Term Loan B by $250 million (Add-On)
Net proceeds expected to fund general corporate purposes and associated fees
Add-On expected to have the same terms as the existing Term Loan B; completion not assured
Lender presentation to be posted to the investor relations section of the website on October 19, 2026
On October 16, 2026, Curis agreed to sell 16,666,680 shares, or pre-funded warrants in place of shares, with accompanying common warrants for up to 16,666,680 shares, at a combined price of $0.51 per share. Gross proceeds are expected to be about $8.5 million before placement agent fees and expenses, with closing expected on or about October 19, 2026. The company also agreed to lower the exercise price of its January and August 2026 warrants to $0.60, and the new share count and warrants would add to the shares outstanding for existing holders.
Offering of 16,666,680 shares or pre-funded warrants, plus common warrants for up to 16,666,680 shares, at a combined $0.51 per share
Gross proceeds expected to be about $8.5 million, before placement agent fees and offering expenses; placement agents to receive a 6.5% cash fee
New common warrants have a $0.60 exercise price, become exercisable six months after issuance, and terminate April 19, 2032
January 2026 and August 2026 warrants to be amended to a reduced exercise price of $0.60; proceeds expected to fund operations through initial CLL data in 5-10 patients in December 2026
On October 13, 2026, NextBoat subsidiary Off The Hook Yacht Sales NC, LLC issued a subordinated promissory note to BPC Management, LLC for advances of up to $2.2 million to fund short-term working capital. The note carries 15.0% simple interest, a 2% origination fee and 90-day maturities, and NextBoat guaranteed Off The Hook's obligations, while the company's controlling stockholder and an affiliate pledged company shares as security, which could lead to a change in control if the lender forecloses.
Initial advance of $1.0 million funded October 13, 2026; a second advance of up to $1.2 million may be made on or before December 31, 2026
Advances bear 15.0% simple interest, carry a 2% origination fee and mature 90 days after funding
Ruegg Capital Group, Inc., an affiliate of Chairman and President Jason Ruegg, pledged shares with collateral value of not less than $5.0 million
Filing states that foreclosure on the pledged shares after an event of default could result in a change in control of the company
Unitil Energy Systems, a subsidiary of Unitil Corporation, sold $60 million of first mortgage bonds on October 14, 2026, in two series: $30 million at 5.72% due 2036 and $30 million at 5.87% due 2038. The company plans to use the proceeds to refinance existing debt and for general corporate purposes, and the bonds carry a fall-away collateral release that would raise the coupons by 0.10 percentage points.
Series T: $30 million, 5.72% coupon, due October 14, 2036
Series U: $30 million, 5.87% coupon, due October 14, 2038
Coupons rise to 5.82% (Series T) and 5.97% (Series U) if collateral is released, per the filing
Proceeds planned for refinancing existing debt and general corporate purposes
FrontView Operating Partnership, the operating partnership of FrontView REIT, entered Amendment No. 5 to its Credit Agreement on October 15, 2026, extending the maturity of its revolving credit facility and term loans to October 3, 2028. The amendment also lowers certain interest rate margins and replaces the revolver's usage-based commitment fee with a facility fee, which shareholders may see as lower borrowing costs and a longer repayment runway.
Amendment No. 5 dated October 15, 2026, extends the revolving credit facility and term loans to October 3, 2028.
Revolver margins before an investment-grade rating range from 1.00% to 1.65%, down from the prior terms, which the filing does not state.
Revolver usage-based commitment fee replaced with a facility fee of 0.15% to 0.30%, based on leverage ratio, before an investment-grade rating.
Full terms will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
Integra LifeSciences entered a $1.65 billion amended and restated credit agreement and closed a $450 million private offering of 9.500% senior secured notes due 2033, both on October 19, 2026. The company used the proceeds and new borrowings to repay in full its Existing Credit Agreement, which had a $1.3 billion revolver and a $775 million term loan. The filing shows new debt and higher-cost secured borrowing terms, but it does not report earnings or guidance changes.
Notes: $450 million principal, 9.500% interest, payable semi-annually, maturing November 1, 2033
Credit agreement: $600 million revolver and $600 million term loan A (five-year), plus $450 million term loan B (seven-year)
Term Loan B applicable rate is 4.25%; revolver and term loan A initially 3.00%, adjusting to 2.00% to 3.25% after the December 31, 2026 quarter
Existing $1.3 billion revolver and $775 million term loan were repaid in full with no early termination penalties
Vail Resorts and its subsidiaries signed a First Amendment to the Tenth Amended and Restated Credit Agreement with Bank of America, N.A., as administrative agent, on October 16, 2026. The amendment removes the board composition provision from the credit agreement's Change of Control Transaction definition and removes the administrative agent's approval requirement for financial hedges. The filing does not state a financial effect, and the amendment's full text will be filed later.
Agreement dated October 16, 2026, amends the credit agreement dated February 9, 2026
Change of control definition no longer counts changes in a majority of the board over any twelve-month period
Voting equity ownership and control triggers are unchanged
Financial hedges no longer need administrative agent approval
On October 16, 2026, Enerpac Tool Group entered into an Amended and Restated Credit Agreement with PNC Bank as administrative agent, replacing its September 2022 facility that was due to mature in September 2027. The new agreement provides a $550 million revolving credit facility and a $300 million term loan, both maturing October 16, 2031, and initial borrowings were used to repay the existing debt and pay fees.
Revolving credit facility of $550 million, including a $200 million sublimit for Euro, Pound Sterling or other agreed foreign currency borrowings
$300 million term loan with quarterly principal payments of $0.9375 million starting March 1, 2028, rising over time, and the remaining balance due at maturity on October 16, 2031
Initial interest at term SOFR plus 1.125%, with margins adjusted by net leverage ratio; the company may request up to $425 million in additional facility capacity, subject to lender commitments
OS Therapies said on October 15, 2026 that seven holders exercised or pre-funded 5,517,253 existing warrants at a reduced price of $1.30 per share, bringing in about $7.2 million in gross proceeds before fees. In exchange, the company issued new five-year warrants for the same number of shares at $1.40, and the company says the offer could bring about $12.3 million in total if all existing warrants are exercised. Because the new warrants add potential share issuance, the deal provides near-term capital but also raises potential dilution for existing shareholders.
Initial closing on October 15, 2026: seven holders exercised or pre-funded warrants for 5,517,253 shares at $1.30 per share, for about $7.2 million gross.
New warrants issued for 5,517,253 shares at $1.40 per share, expiring five years from issuance; if all existing warrants are exercised, up to 9,448,060 new warrant shares could be issued.
Company agreed to pay a solicitation agent a 7.0% cash fee on gross proceeds plus a $25,000 expense allowance; the offer expires at 11:59 p.m. Eastern on October 30, 2026.
Company plans to file a resale registration statement by November 30, 2026, and says proceeds will fund Herlystic clinical, regulatory and commercial preparation work.
Dogwood Therapeutics agreed on October 19, 2026 to sell 4,098,360 shares of common stock at $1.22 per share to Sealbond Limited, a subsidiary of its largest shareholder, in a private placement with expected gross proceeds of about $5 million before offering expenses. The company says the proceeds will extend its operational runway through March 2027 and fund Phase 3 preparatory work, and the issuance adds new shares that dilute existing holders.
4,098,360 shares of common stock at $1.22 per share, with expected gross proceeds of about $5 million before offering expenses
Sealbond beneficially owned about 63.9% of outstanding common stock before the placement and is considered an affiliate
Closing is expected on or before October 29, 2026; the company must file a resale registration statement by the 15th day after the October 19, 2026 agreement
The press release says proceeds will fund Phase 3 preparatory activities and extend runway through March 2027, ahead of HAL-CINP Phase 2b topline data expected in November 2026
On October 16, 2026, Teamshares Continuity Holdings LLC, a subsidiary of Teamshares Inc, entered into a $130.0 million senior secured term loan and used it, with cash on hand, to repay in full the $150.0 million Existing Credit Agreement, with a payoff of about $152.8 million including accrued interest. The new loan carries a rate of one-month Term SOFR (3.00% floor) plus 9.50%, down from 11.00% on the old facility, but while it is outstanding the Company may not pay dividends or repurchase its equity without the agent's consent.
New $130.0 million term loan matures on the fourth anniversary of the October 16, 2026 closing date, with quarterly principal payments starting December 31, 2026
Interest rate is one-month Term SOFR (3.00% floor) plus 9.50%, versus Term SOFR (3.00% floor) plus 11.00% on the repaid facility
Company expects annual interest expense to decrease by approximately $5 million at current SOFR levels, per the press release
Credit agreement restricts dividends and equity repurchases without Agent consent, limiting shareholder payouts while the loan is outstanding
Marker Therapeutics said the FDA awarded it $2.6 million through its Orphan Products Clinical Trials grants program to support a Phase 1 study of MT-601 in patients with locally advanced unresectable pancreatic cancer. The company describes the funding as non-dilutive, and it expects clinical initiation of the study in the first quarter of 2027.
FDA award of $2.6 million under the Orphan Products Clinical Trials grants program, announced October 19, 2026
Grant will support a Phase 1 study of lead candidate MT-601 in locally advanced unresectable pancreatic cancer
FDA received 66 applications and selected six projects for funding in fiscal year 2026
Marker expects to begin clinical initiation of the pancreatic cancer study in the first quarter of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.